Navigation Links
Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Date:10/25/2007

PLYMOUTH MEETING, Pa., Oct. 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) is providing the following summary of highlights related to the successful first Phase 1 study of trodusquemine and additional preclinical data expanding the support for selectivity and specificity of the drug in preclinical models from the North American Association for the Study of Obesity (NAASO) Annual Meeting in New Orleans:

-- Interim results from Study MSI-1436C-101 presented at Genaera's poster

session, "First in Human Use of MSI-1436 (Trodusquemine), a Centrally

and Peripherally Acting Selective PTP1B Inhibitor," demonstrated that

the drug was safe and well tolerated by the healthy, overweight and

obese volunteers at doses well above the anticipated therapeutic dose

level with no evidence of serious adverse events. No pharmacodynamic

effects were anticipated or observed in this study with a single dose

of MSI-1436.

-- There were no significant changes in vital signs, cardiovascular

parameters (as assessed by ECG and cardiac telemetry), clinical

laboratory or hematology parameters. Moreover, pharmacokinetic (PK)

profiles of trodusquemine in the first five cohorts of the study showed

a consistent pattern with minimal subject-to-subject variability and

linearity was observed across the range of doses studied. Values for a

wide range of endocrine and metabolic biomarkers as well as evaluations

of mood and cognition were also found to be stable across the subjects

receiving all levels of the drug or placebo during the trial.

-- Consequently, these positive Study MSI-1436C
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. XTL Provides Update on Phase I Clinical Trial of XTL-2125
11. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral ... Executive Officer, will present live at VirtualInvestorConferences.com on ... 6, 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... live, interactive online event where investors are invited ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... Piper Jaffray Health Care Conference on Wednesday, November 30, ... Palace Hotel in New York. The presentation will be ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: The 2011 Vibrio Diagnostics ... Forecasts by Country http://www.reportlinker.com/p0444741/The-Vibrio-Diagnostics-Market-US-Europe-JapanTest-Volume-and-Sales-Forecasts-by-Country.html ... detailed analysis of the Vibrio diagnostics market in ...
Cached Medicine Technology:The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 2The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 3The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 4
(Date:8/4/2015)... Angeles, CA (PRWEB) , ... August 04, 2015 , ... ... study that found financial incentives to be a viable method for encouraging people to ... wager money on the future of their weight loss success, adding a financial incentive ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... ... 04, 2015 , ... Members receiving care from a doctor who participates in ... that is nine percent lower -- than those members at traditional doctor practices, according ... programs. , “The promise of patient-centered, or value-based, care to deliver better quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are researching online ... physician. In an effort to share more and better information with these savvy ... publicly share patient satisfaction ratings and comments about its doctors and advanced practice ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... you are pregnant, here,s another reason to work out: ... developing neurodegenerative diseases, such as Alzheimer,s, later in life. ... FASEB Journal ( http://www.fasebj.org ) shows that mice ... Alzheimer,s disease showed fewer signs of the disease and ...
... of the leading causes of death and morbidity worldwide, ... 2008, the worldwide cost of cancer due to premature ... to be US$895 billion. An expert report from ... of some of the world,s leading cancer specialists, from ...
... Netherlands: Mothers who are exposed to particular agents during pregnancy ... asthma, according to new research. The study will ... Society,s Annual Congress in Amsterdam. It is ... and chemicals it can cause asthma. However, there has been ...
... The Netherlands: A new study has shown that people ... reduced lung function are at a serious risk of ... presented today (26 September 2011) at the European Respiratory ... COPD and reduced lung function should be routinely screened ...
... and unspoken clues exchanged by patients and doctors exert ... study by the University of Michigan Health System. Researchers ... interviews with participants to help elucidate signals sent and ... The method shows promise for improving medical decision ...
... of personalised medicine, gains in cancer survival over the ... trials with less stringent evidence criteria, a researcher told ... 26 Sept). The introduction of targeted treatments means ... most effective way of getting new treatments to cancer ...
Cached Medicine News:Health News:Pregnant women who exercise protect their offspring against long-term neurodegenerative diseases 2Health News:Unequal access to cancer care can no longer be tolerated 2Health News:Unequal access to cancer care can no longer be tolerated 3Health News:A mother's occupation while pregnant can cause asthma in children 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 3Health News:Smaller, faster trials can improve cancer patient survival 2Health News:Smaller, faster trials can improve cancer patient survival 3
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Sickle Edge blade, straight, 5.0 mm W x 84 mm long. Specially designed for superior visibility and easy access into the ear canal, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: